Skip to main content
. Author manuscript; available in PMC: 2024 Nov 8.
Published in final edited form as: JCO Precis Oncol. 2024 Oct 21;8:e2400275. doi: 10.1200/PO.24.00275

FIG 3.

FIG 3.

A hypothetical phase I clinical trial using the TALE design. Each table represents a stage of the trial, and the number in each cell represents the number of DLTs/number of enrolled patients. The set Lk includes all dose combinations that are assigned at stage k. DLTs, dose-limiting toxicities; TALE, Toxicity Adaptive Lists Design.